Publications

52 items matching your search terms.

MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer

Portman, N.; Chen, J.; Lim, E.

Frontiers in Oncology 11 :777867, 2021 10.3389/fonc.2021.777867

Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials

Brown, L. J.; Meredith, T.; Yu, J.; Patel, A.; Neal, B.; Arnott, C.; Lim, E.

Cancers (Basel) 13 (21) :5527, 2021 10.3390/cancers13215527

Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic

Kumar, S.; Freelander, A.; Lim, E.

Cancers 13 (19) :4972, 2021 10.3390/cancers13194972

The management of HER2-positive early breast cancer: Current and future therapies

Chen, J.; Colosimo, M.; Lim, E.

Asia Pacific Journal of Clinical Oncology 17 Suppl 6 :3-12, 2021 10.1111/ajco.13655

A single-cell and spatially resolved atlas of human breast cancers

Wu, S. Z.; Al-Eryani, G.; Roden, D. L.; Junankar, S.; Harvey, K.; Andersson, A.; Thennavan, A.; Wang, C.; Torpy, J. R.; Bartonicek, N.; Wang, T.; Larsson, L.; Kaczorowski, D.; Weisenfeld, N. I.; Uytingco, C. R.; Chew, J. G.; Bent, Z. W.; Chan, C. L.; Gnanasambandapillai, V.; Dutertre, C. A.; Gluch, L.; Hui, M. N.; Beith, J.; Parker, A.; Robbins, E.; Segara, D.; Cooper, C.; Mak, C.; Chan, B.; Warrier, S.; Ginhoux, F.; Millar, E.; Powell, J. E.; Williams, S. R.; Liu, X. S.; O'Toole, S.; Lim, E.; Lundeberg, J.; Perou, C. M.; Swarbrick, A.

NATURE GENETICS 53 (9) :1334-1347, 2021 10.1038/s41588-021-00911-1

DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity

Du, Q.; Smith, G. C.; Luu, P. L.; Ferguson, J. M.; Armstrong, N. J.; Caldon, C. E.; Campbell, E. M.; Nair, S. S.; Zotenko, E.; Gould, C. M.; Buckley, M.; Chia, K. M.; Portman, N.; Lim, E.; Kaczorowski, D.; Chan, C. L.; Barton, K.; Deveson, I. W.; Smith, M. A.; Powell, J. E.; Skvortsova, K.; Stirzaker, C.; Achinger-Kawecka, J.; Clark, S. J.

Cell Reports 36 (12) :109722, 2021 10.1016/j.celrep.2021.109722

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Alves, C. L.; Ehmsen, S.; Terp, M. G.; Portman, N.; Tuttolomondo, M.; Gammelgaard, O. L.; Hundebol, M. F.; Kaminska, K.; Johansen, L. E.; Bak, M.; Honeth, G.; Bosch, A.; Lim, E.; Ditzel, H. J.

Nature Communications 12 (1) :5112, 2021 10.1038/s41467-021-25422-9

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition

Aziz, D.; Portman, N.; Fernandez, K. J.; Lee, C.; Alexandrou, S.; Llop-Guevara, A.; Phan, Z.; Yong, A.; Wilkinson, A.; Sergio, C. M.; Ferraro, D.; Etemadmoghadam, D.; Bowtell, D. D.; kConFab, Investigators; Serra, V.; Waring, P.; Lim, E.; Caldon, C. E.

NPJ Breast Cancer 7 (1) :111, 2021 10.1038/s41523-021-00312-x

Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models

Chew, N. J.; Lim Kam Sian, T. C. C.; Nguyen, E. V.; Shin, S. Y.; Yang, J.; Hui, M. N.; Deng, N.; McLean, C. A.; Welm, A. L.; Lim, E.; Gregory, P.; Nottle, T.; Lang, T.; Vereker, M.; Richardson, G.; Kerr, G.; Micati, D.; Jarde, T.; Abud, H. E.; Lee, R. S.; Swarbrick, A.; Daly, R. J.

BREAST CANCER RESEARCH 23 (1) :82, 2021 10.1186/s13058-021-01461-4

Case Report: Paclitaxel-Induced Pneumonitis in Early Breast Cancer: A Single Institution Experience and Review

Ardolino, L.; Lau, B.; Wilson, I.; Chen, J.; Borella, L.; Stone, E.; Lim, E.

Frontiers in Oncology 11 :701424, 2021 10.3389/fonc.2021.701424

Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis

Wu, S. Z.; Roden, D. L.; Al-Eryani, G.; Bartonicek, N.; Harvey, K.; Cazet, A. S.; Chan, C. L.; Junankar, S.; Hui, M. N.; Millar, E. A.; Beretov, J.; Horvath, L.; Joshua, A. M.; Stricker, P.; Wilmott, J. S.; Quek, C.; Long, G. V.; Scolyer, R. A.; Yeung, B. Z.; Segara, D.; Mak, C.; Warrier, S.; Powell, J. E.; O'Toole, S.; Lim, E.; Swarbrick, A.

Genome Medicine 13 (1) :81, 2021 10.1186/s13073-021-00885-z

Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer

Freelander, A.; Brown, L. J.; Parker, A.; Segara, D.; Portman, N.; Lau, B.; Lim, E.

Genes 12 (2) 2021 10.3390/genes12020285

The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer

Hickey, T. E.; Selth, L. A.; Chia, K. M.; Laven-Law, G.; Milioli, H. H.; Roden, D.; Jindal, S.; Hui, M.; Finlay-Schultz, J.; Ebrahimie, E.; Birrell, S. N.; Stelloo, S.; Iggo, R.; Alexandrou, S.; Caldon, C. E.; Abdel-Fatah, T. M.; Ellis, I. O.; Zwart, W.; Palmieri, C.; Sartorius, C. A.; Swarbrick, A.; Lim, E.; Carroll, J. S.; Tilley, W. D.

NATURE MEDICINE 27 (2) :310-320, 2021 10.1038/s41591-020-01168-7

CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care

Hui, R.; de Boer, R.; Lim, E.; Yeo, B.; Lynch, J.

Asia Pacific Journal of Clinical Oncology 17 Suppl 1 :3-14, 2021 10.1111/ajco.13555

Estrogen receptor positive breast cancer patient derived xenograft models in translational research.

Chia, K.; Freelander, A.; Kumar, S.; Parker, A.; Segara, D.; Portman, N.; Lim, E.

Current Opinion in Endocrine and Metabolic Research 15 :31-36, 2020

Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer

de Boer, R.; Hui, R.; Lim, E.; Yeo, B.; Zdenkowski, N.

Asia-Pacific Journal of Clinical Oncology 16 Suppl 5 :3-14, 2020 10.1111/ajco.13461